Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.BACKGROUND
 The current phase 2 study evaluated the efficacy and tolerability of dovitinib, an FGFR inhibitor, in patients with advanced SCC of the lung.


 Dovitinib at a dose of 500 mg was administered orally, once daily, on days 1 to 5 of every week, followed by 2 days off.  The median duration of dovitinib administration (28 days per cycle) was 2.5 months (range, 0.7-8.6 months).  Treatment with dovitinib demonstrated modest efficacy in patients with advanced SCC with FGFR1 amplification.  Further studies to evaluate other biomarkers correlated with the efficacy of dovitinib in patients with SCC are warranted. 
dovitinib
The current phase 2 study evaluated the efficacy and tolerability of dovitinib, an FGFR inhibitor, in patients with advanced SCC of the lung.



FGFR inhibitor
The most common grade 3 or higher adverse events were fatigue (19.2%), anorexia (11.5%), and hyponatremia (11.5%) (event severity was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]).



National Cancer Institute Common Terminology Criteria for Adverse Events